DR. GAIL E. GILLENWATER NAMED VICE PRESIDENT OF CLINICAL AND REGULATORY AFFAIRS OF VYREX CORPORATION

SAN DIEGO, July 8 /PRNewswire/ -- Vyrex Corporation (Nasdaq Small Cap: VYRX, VYRXU, VYRXW) today announced that Gail E. Gillenwater, Ph.D. has been named Vice President of Clinical and Regulatory Affairs. Dr. Gillenwater's extensive pre-clinical and clinical drug development experience includes direction of programs at Abbott Laboratories, GenDerm, Chemex, NDA Resources and SIBIA Neurosciences.

"In my drug development experience, I have found that a key ingredient for success is strong leadership, planning and execution of clinical studies," said Dannie H. King, Ph.D., President and COO. "Dr. Gillenwater has honed her skills in guiding the clinical research activities for a number of pharmaceutical companies over the past decade. She has the leadership ability, experience and clinical acumen that Vyrex needs to successfully take its therapeutic candidates through clinical trials. We are very pleased to have her join the Vyrex team."

"We have a number of drug candidates that will be entering the clinical trail process in the next few years," said Sheldon S. Hendler, Ph.D., M.D., Chairman and CEO. "Dr. Gillenwater brings experience in the overall New Drug Application (NDA) process which will be instrumental as we prepare Investigational New Drug (IND) submissions and implement our clinical programs. Also of great value to Vyrex, is her experience in directing toxicology, analytical and manufacturing projects."

Dr. Gillenwater joins Vyrex from SIBIA where she was the Director of Clinical Studies for the past three years. Prior to joining SIBIA, Dr. Gillenwater was Managing Director and Director of Clinical Development for NDA Resources, a firm which specializes in the management of clinical study activities. Earlier she served as Director of Clinical Research at Chemex, Director of Clinical Research and Regulatory Affairs at GenDerm Corporation and Senior Clinical Research Associate at Abbott Laboratories.

Dr. Gillenwater holds a B.A. degree from Michigan State University, an M.A. from Georgia State University, and a Ph.D. in Pharmacology from Loyola University Stritch School of Medicine.

Vyrex is developing therapeutic products including redox modulators, which are designed to promote cell maintenance and repair by reducing the damaging effects of free radicals. Therapeutic targets include infectious diseases, cancer, ear disorders, and respiratory, cardiovascular and neurodegenerative diseases. Vyrex also has a unique and enabling gene and protein discovery platform called CD-Tagging(TM). This technology will be used by Vyrex to identify genes and proteins involved in diseases with the goal of developing new diagnostic and therapeutic products.

There can be no assurance that the opinions, beliefs or predictions made by Vyrex regarding its technologies will be realized in whole or in part. Any predictions or representations, written or oral, concerning the information contained herein, or opinions regarding future events are solely forward looking and actual results may be materially different from such predictions. There can be no assurance given as to the actual results of future events.

    -0-                       7/8/96

/CONTACT: Dannie H. King, Ph.D., President and COO of Vyrex Corporation, 619-454-4446; or Media: Linda Seaton of Mentus, Inc., 619-455-5500/

(VYRX)

CO: Vyrex Corporation ST: California IN: MTC SU: PER

MO-BB -- LAM010 -- 0154 07/08/96 08:12 EDT